Orogen Royalties Inc
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 2020-01-01
- Employees
- 10K
- Market Cap
- -
- Website
- http://www.organon.com
- Introduction
Organon & Co. is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women’s health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.
Taste Test Between Desloratadine and Cetirizine Syrup in Children (Study P03826)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-11-20
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 204
- Registration Number
- NCT00794794
Preference for Clarinex Tablets vs Allegra Tablets in Patients With Seasonal Allergies (P03178)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-11-20
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 118
- Registration Number
- NCT00794768
Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03180)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-11-20
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 124
- Registration Number
- NCT00794846
Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03181)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-11-20
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 122
- Registration Number
- NCT00794495
Preference for Clarinex Tablets vs. Zyrtec Tablets in Patients With Allergies (P03182)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-11-20
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 118
- Registration Number
- NCT00794599
Preference for Clarinex Tablets vs. Allegra Tablets in Patients With Seasonal Allergies (Study P03179)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-11-20
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 122
- Registration Number
- NCT00794248
The Effect of Desloratadine and Levocetirizine on Nasal Obstruction (Study P03609)
- First Posted Date
- 2008-11-11
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 81
- Registration Number
- NCT00789152
A Study of MK0663/Etoricoxib for Post-Abdominal Hysterectomy Surgery Pain (0663-097)(COMPLETED)
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-11-11
- Last Posted Date
- 2022-02-09
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 430
- Registration Number
- NCT00788710
Single Dose Crossover Study of Patient Preference for Unscented Nasonex® Nasal Spray Versus Scented Flonase® Nasal Spray (Study P04208)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 100
- Registration Number
- NCT00783458
Efficacy and Safety of Desloratadine vs. Fexofenadine 180 mg. vs. Placebo for Treating Seasonal Allergic Rhinitis (SAR)(Study P04053)(COMPLETED)
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-10-31
- Last Posted Date
- 2024-08-15
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 722
- Registration Number
- NCT00783211
© Copyright 2024. All Rights Reserved by MedPath